⌘+K

Post-results note

Validation trial progressing, but eyes on the cash runway

Niels Granholm-Leth

Jesper Ingildsen

Oliver Røst Benneballe

2026-11-19

14:01 CET

The Q3 numbers were slightly above our expectations, driven by non-core products. However, we expect rising R&D costs in 2027 and see a need for additional funding. We reiterate our fair value range of DKK0.5–3.0, including a WACC of 17.0%.

Q3 trading update. Q3 sales and EBITDA were slightly above our forecasts supported by non-core products. Cash burn was in line with our expectation (Q3 cash: DKK53.2m). We raise our 2026e but trim 2027e EBITDA due to higher R&D costs for the validation trial, partly offset by higher RSUO sales at attractive gross margins. As of Q3, 59 US hospitals contributed to NGAL RSUO sales, and we find BioPorto likely to exceed the target of 60 hospitals in 2026.

ProNephro US adult validation trial progressing as planned, but focus is on cash runway. Expansion of the ProNephro NGAL trial to 900 patients to meet FDA requirements comes at a cost. We now estimate 2027 R&D costs of DKK53m, implying a funding need of ~DKK20m. On our calculations, we would not rule out BioPorto seeking external funding, even when factoring in the USD1.5m earnout from the antibody divestment potentially received over the next three years.

FDA approval of ProNephro in adults could be transformative. ProNephro is already FDA-approved for paediatric use, but we believe the FDA label expansion to adults is the key value driver, potentially unlocking ~57% of BioPorto’s estimated USD3bn TAM. Under the partnerships with Roche and Beckman Coulter, we see scope for scaling sales at attractive margins. However, it will depend on: 1) KDIGO guideline inclusion; 2) label expansion to adults; and 3) the ability to bridge the patent expirations in Q3 2028. US adults account for ~71% of our NPV SOTP.

Fair value range of DKK0.5–3.0 per share reiterated, using a risk-adjusted SOTP NPV (17.0% WACC, 1.3x beta and 5% liquidity premium): the upper end reflects approval of ProNephro NGAL in the adult indication alongside 10% additional revenue growth and 1% additional annual EBITDA margin expansion in our 20-year forecast period; the lower end assumes no FDA approval of ProNephro for adults and negative brand perception spill-over to RSUO.

Denmark

Healthcare

Latest share price

DKK

0.9

-1.05%

20 Nov 2026 16:59 CET

Fair value range

DKK

0.5

—

3.0

9 Apr 2026

Market cap

DKK

465

m

Key stats

Year

2026e

EPS

-0.03

EPS (Adj.)

-0.03

Sales Growth

-5.46%

EPS Growth (Adj.)

P/E

P/E (Adj.)

EV/EBITA

-6.4

EV/EBITDA

-6.7

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB